AngioDynamics Q1 FY2027: Med Tech Growth Accelerates, Guidance Reiterated
ANGO sits 48% above its 52-week low of $9.39 on elevated volume (2.0× avg).
Summary
AngioDynamics posted Q1 FY2027 revenue of $80.9M (+6.9% YoY) with Med Tech up 13.2%, adjusted EBITDA more than doubling to $5.0M, and reiterated full-year guidance. The FDA also approved the RELIEF study for NanoKnife in BPH.
Updates
· SEC 10-Q — 10-Q confirms Q1 FY2027 net loss of $7.1M, operating loss of $7.3M, and cash used in operations of $15.3M.
Key Events · Earnings and Guidance · ANGO
-
Q1 Revenue Beats Consensus
Net sales of $80.9M, up 6.9% YoY, slightly above the $80.5M consensus. Med Tech grew 13.2% to $39.9M, led by Auryon (+14.7%) and NanoKnife (+29.0%).
-
Profitability Inflection
Adjusted EBITDA more than doubled to $5.0M from $2.2M prior year. GAAP gross margin expanded 410 bps to 59.4%, including a $1.2M tariff refund benefit.
-
FY2027 Guidance Reiterated
Full-year guidance maintained: Net Sales $336-341M, Med Tech growth +12-15%, Adjusted EBITDA $13-16M, Adjusted EPS ($0.29)-($0.24).
-
Cash Position Declines
Cash fell to $34.0M from $53.9M at FY2026 year-end, with $15.3M used in operations during Q1. Management expects positive operating cash flow for FY2027.
Analysis · ANGO · Industrial Applications And Services
AngioDynamics delivered Q1 FY2027 revenue of $80.9M, up 6.9% year-over-year, with Med Tech growing 13.2% to $39.9M — the eighth consecutive quarter of double-digit Med Tech growth. Adjusted EBITDA more than doubled to $5.0M from $2.2M, and gross margin expanded 410 basis points to 59.4%, helped by a $1.2M tariff refund. The company reiterated full-year guidance of $336-341M in sales and $13-16M in adjusted EBITDA. Cash declined to $34.0M from $53.9M at year-end, reflecting $15.3M of operating cash burn in the quarter, though management expects positive operating cash flow for the full year. The FDA also cleared the RELIEF study for NanoKnife in benign prostatic hyperplasia, expanding the platform's addressable market beyond oncology.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 28.5% of the 1688 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANGO was trading at $13.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $596.8M. The 52-week trading range was $9.39 to $16.29. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.